Innovate UK
Register
Register
Register

BioGene Ltd

www.biogene.com/kimbolton, United Kingdom

About

BIOGENE LTD – Innovative Molecular Testing at the Point of Decision

BIOGENE LTD is an established UK life sciences company with over 30 years of experience in molecular technologies. Together with our associated R&D company, BG Research Ltd, which has held ISO 13485 certification since 2020, we develop proprietary technologies for rapid, affordable and decentralised molecular testing.

Our flagship innovation, CENOS™, is a compact, portable RT-qPCR platform designed to bring sophisticated molecular analysis directly to the point of need, without conventional laboratory infrastructure or specialist personnel.

CENOS™ – Key Technological Advantages

  • Extraction-free molecular testing: Direct qPCR/RT-qPCR from crude biological samples, including swabs, saliva and blood, without conventional nucleic acid extraction.

  • Rapid results: Sample preparation in seconds, with molecular results typically available in approximately 30 minutes.

  • Portable and low-power: Lightweight instrumentation (under 3kg), operating from a 15V power supply.

  • Proprietary enzyme technology: Highly inhibitor-tolerant RT-PCR chemistry supporting direct analysis of challenging biological matrices.

  • Multiplex molecular analysis: Integrated fluorescence detection, micro-spectrometer technology and automated result interpretation.

  • Lyophilised reagent technology: Reagent formulations designed to simplify handling, storage and deployment.

  • Minimal infrastructure: Designed for operation by non-specialist personnel in field, farm, community and decentralised healthcare settings.

Applications and Scientific Validation

Our development programme spans veterinary, human and zoonotic infectious diseases, including avian influenza, Newcastle disease, foot-and-mouth disease, African swine fever, peste des petits ruminants and emerging viral threats.

CENOS has been independently evaluated through collaborations with leading UK research institutions, including the Animal and Plant Health Agency (APHA) and The Pirbright Institute. Our work with APHA on direct molecular testing for avian influenza and Newcastle disease has also been reported in a scientific preprint.Also African Swine Flu Seneca Valley and Foot and Mouth Disease

UK–Singapore Collaborative R&D Opportunity

BIOGENE is seeking innovative Singapore-based companies to establish a collaborative R&D partnership under the Innovate UK–Singapore funding competition.

Areas of mutual interest include:

  • Novel veterinary, human and zoonotic molecular assay development.

  • Advanced enzyme technologies, reagent stabilisation and lyophilisation.

  • Direct-from-sample processing and simplified sample preparation.

  • Microfluidics, miniaturisation and integration of molecular analysis.

  • Multiplex optical detection, signal processing and analytical sensitivity improvements.

  • Decentralised molecular testing for infectious disease surveillance, outbreak preparedness and One Health applications.

BIOGENE brings an established proprietary platform, in-house molecular biology and engineering capabilities, existing institutional validation programmes and an emerging commercialisation pathway.

We are particularly interested in Singapore partners with complementary proprietary technologies, scientific expertise or established R&D capabilities, enabling both parties to develop innovative products with significant international commercial potential.

Our goal is to make rapid molecular testing accessible wherever and whenever decisions need to be made – At Patient Testing™.

Contact: nelson@biogene.com

Website: www.biogene.com

Social media

Representatives

Managing Director

BioGene Ltd